Which super funds hold Novozymes A/S?

As at 31 December 2025, 12 Australian super investment options in our dataset held Novozymes A/S, the largest weighting being 0.01% in International Shares (Accumulation) (AustralianSuper).

Options holding it

12

Largest weighting

0.01%

International Shares (Accumulation) · AustralianSuper

Funds & options holding Novozymes A/S

Australian super investment options disclosing a holding in Novozymes A/S. Figures aggregate each option's disclosed line items for this security, as at each option's own reporting date.

FundPhaseOptionWeightingValue (AUD)As at
AustralianSuperAccumulationBalanced (Accumulation)
0.00%
$5,170,73831 December 2025
AustralianSuperAccumulationHigh Growth (Accumulation)
0.00%
$1,161,04431 December 2025
AustralianSuperRetirementBalanced (Income)
0.00%
$684,77631 December 2025
AustralianSuperAccumulationInternational Shares (Accumulation)
0.01%
$607,82631 December 2025
AustralianSuperAccumulationIndex Diversified (Accumulation)
0.01%
$398,70231 December 2025
AustralianSuperRetirementIndex Diversified (Income)
0.01%
$181,32831 December 2025
AustralianSuperRetirementConservative Balanced (Income)
0.00%
$141,94631 December 2025
AustralianSuperAccumulationConservative Balanced (Accumulation)
0.00%
$117,08131 December 2025
AustralianSuperRetirementInternational Shares (Income)
0.01%
$90,52331 December 2025
AustralianSuperRetirementHigh Growth (Income)
0.00%
$78,56831 December 2025
AustralianSuperAccumulationStable (Accumulation)
0.00%
$48,96931 December 2025
AustralianSuperRetirementStable (Income)
0.00%
$45,10731 December 2025

This page surfaces figures disclosed by the funds themselves under Portfolio Holdings Disclosure (Schedule 8D), each as at the date shown. It is factual disclosure information, not financial advice or a recommendation.

Methodology — how holdings are sourced, resolved and aggregated.

LookThrough shows the actual holdings inside Australian super funds, with cross-fund look-through.

  • 4 of 86 funds
  • 36 of 111 options reviewed
  • 7,010 of 7,168 securities reviewed

© 2026 LookThrough. Factual disclosure information — not financial advice, a rating or a recommendation.